We have opened enrollment for the Phase 2 study of BPC-101 in patients with HR+/HER2- metastatic breast cancer who have progressed on a prior CDK4/6 inhibitor plus endocrine therapy. The study will randomize 240 participants across eight clinical trial sites.
The primary endpoint is progression-free survival. Secondary endpoints include overall response rate, clinical benefit rate, and safety. The protocol and site list are available on the trials page.
BPC-101 is an investigational candidate. It has not been approved by any regulatory authority.
Investigational candidates mentioned in this article have not been approved by any regulatory authority.